Skip to main content

CORRECTION article

Front. Nephrol., 05 January 2023
Sec. Onconephrology
Volume 2 - 2022 | https://doi.org/10.3389/fneph.2022.1129134
This article is part of the Research Topic Women in Onconephrology: 2022 View all 6 articles

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

This article is a correction to:

  1. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

    1. Read original article
T. Van Meerhaeghe*T. Van Meerhaeghe1*J.F. BaurainJ.F. Baurain2O. BechterO. Bechter3C. Orte CanoC. Orte Cano4V. Del MarmolV. Del Marmol4A. DevresseA. Devresse5P. DoubelP. Doubel6M. HanssensM. Hanssens7R. HellemansR. Hellemans8D. LienardD. Lienard4A. RuttenA. Rutten9B. SprangersB. Sprangers10A. Le MoineA. Le Moine1S. AspeslaghS. Aspeslagh11
  • 1Department of Nephrology, Hôpital Erasme – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • 2Department of Oncology, Clinique Universitaire Saint-Luc – Université Catholique de Louvain (UCLouvain), Brussels, Belgium
  • 3Department of Oncology, Universitair Ziekenhuis (UZ) Leuven – Katholieke Universiteit Leuven (KUL), Leuven, Belgium
  • 4Department of Dermatology, Hôpital Erasme – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • 5Department of Nephrology, Clinique Universitaire Saint-Luc – Université Catholique de Louvain (UCLouvain), Brussels, Belgium
  • 6Department of Nephrology, Academisch Ziekenhuis (AZ) Groeninge, Kortrijk, Belgium
  • 7Department of Oncology, Academisch Ziekenhuis (AZ) Groeninge, Kortrijk, Belgium
  • 8Departement of Nephrology, Universitair Ziekenhuis (UZ) Antwerpen, Antwerpen, Belgium
  • 9Department of Oncology, GasthuisZuster, Antwerpen, Belgium
  • 10Department of Nephrology, Universitair Ziekenhuis (UZ) Leuven – Katholieke Universiteit Leuven (KUL), Leuven, Belgium
  • 11Department of Oncology, Universitair Ziekenhuis (UZ) Brussel – Vrije Universiteit Brussel (VUB), Brussels, Belgium

A corrigendum on
Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

by Van Meerhaeghe T, Baurain JF, Bechter O, Orte Cano C, Del Marmol V, Devresse A, Doubel P, Hanssens M, Hellemans R, Lienard D, Rutten A, Sprangers B, Le Moine A and Aspeslagh S (2022) 2:1041819. doi: 10.3389/fneph.2022.1041819

In the published article, there was a mistake in the Funding statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.

Funding

TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: cemiplimab, kidney transplant recipients, cutaneous squamous cell carcinoma, immune checkpoint inhibitors, rejection

Citation: Van Meerhaeghe T, Baurain JF, Bechter O, Orte Cano C, Del Marmol V, Devresse A, Doubel P, Hanssens M, Hellemans R, Lienard D, Rutten A, Sprangers B, Le Moine A and Aspeslagh S (2023) Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. Front. Nephrol. 2:1129134. doi: 10.3389/fneph.2022.1129134

Received: 21 December 2022; Accepted: 22 December 2022;
Published: 05 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Van Meerhaeghe, Baurain, Bechter, Orte Cano, Del Marmol, Devresse, Doubel, Hanssens, Hellemans, Lienard, Rutten, Sprangers, Le Moine and Aspeslagh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: T. Van Meerhaeghe, dGVzcy52YW4ubWVlcmhhZWdoZUBlcmFzbWUudWxiLmFjLmJl

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.